Effect of COVID-19 on non-cystic fibrosis bronchiectasis exacerbation rates: a retrospective claims study
A. Åstrand (Mölndal, Sweden), S. Kiddle (Evanston, United States), R. Mudedla (Evanston, United States), S. Porwal (Evanston, United States), K. Chafekar (Evanston, United States), C. Seminario (Gaithersburg, United States), J. Chalmers (Dundee, United Kingdom), I. Psallidas (Cambridge, United Kingdom), I. Psallidas (London, United Kingdom)
Source: International Congress 2022 – Bronchiectasis: 2
Session: Bronchiectasis: 2
Session type: Thematic Poster
Number: 3394
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Åstrand (Mölndal, Sweden), S. Kiddle (Evanston, United States), R. Mudedla (Evanston, United States), S. Porwal (Evanston, United States), K. Chafekar (Evanston, United States), C. Seminario (Gaithersburg, United States), J. Chalmers (Dundee, United Kingdom), I. Psallidas (Cambridge, United Kingdom), I. Psallidas (London, United Kingdom). Effect of COVID-19 on non-cystic fibrosis bronchiectasis exacerbation rates: a retrospective claims study. 3394
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|